The science of psychedelic medicine

2026/02/01 by Joshua S. Siegel, Conor Liston, Ginger E. Nicol +2 · 1 voice
Neuroscience · Pharmacology, Toxicology and Pharmaceutics · Psychology · #Forensic Toxicology and Drug Analysis #Pain Management and Placebo Effect #Psychedelics and Drug Studies

paper · doi:10.1038/s41591-025-04194-5

crossref issued 2026/02/01 · crossref published 2026/02/01 · crossref published-print 2026/02/01 · openalex publication_date 2026/02/01 · crossref published-online 2026/02/06 · crossref created 2026/02/06 · openalex created_date 2026/02/07 · crossref deposited 2026/02/22 · crossref indexed 2026/07/15 · openalex updated_date 2026/07/23

Citations

• Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
• Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
• Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder
• Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
• A Neurotrophic Model for Stress-Related Mood Disorders
• Towards a cognitive neuroscience of consciousness: basic evidence and a workspace framework
• Response of cluster headache to psilocybin and LSD
• Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
• Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
• REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
• Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
• Trial of Psilocybin versus Escitalopram for Depression
• MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
• Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
• Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
• Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs
• Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
• Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
• On Minimizing Risk and Harm in the Use of Psychedelics
• Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report
• Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder
• LSD microdosing in major depressive disorder: results from an open-label trial
• Psychedelics and collective trauma: multisystemic resilience and recovery pathways among Nova festival survivors – a qualitative study
• Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks

Discussions

• My take: This is the strongest review of neuroscience findings to date. Lots more in the article. Read it if you want to stay up to date: doi.org/10.1038/s415... #psychedelicscience [bsky, 1 points, 0 comments]